Core Insights - Conduit Pharmaceuticals is advancing its pipeline with significant progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and intellectual property (IP) expansion, positioning the company for near-term milestones and growth [1][6] R&D Progress - Conduit has partnered with Charles River Laboratories to conduct preclinical studies on glucokinase inhibitors for autoimmune diseases, focusing initially on lupus, with results expected in Q2 2025 [2] - The Phase II clinical trial for AZD1656 is being optimized, targeting systemic lupus erythematosus (SLE) with nephritis and ANCA-associated vasculitis (AAV), designed as a single-center, double-blind, placebo-controlled study [3] Intellectual Property Development - The company is enhancing its IP portfolio at its Cambridge Science Park facility, securing a composition-of-matter patent for AZD1656 Cocrystals from the Japan Patent Office and IP Australia, with pending applications at the USPTO and European Patent Office [4] - Conduit is developing new solid forms of its key assets, including AZD1656, AZD5904, and AZD5658, to strengthen its IP portfolio and support commercialization strategies [4] Formulation Development - Through a strategic agreement with Agility Life Sciences, Conduit is developing novel solid oral-dosage forms for its pipeline assets, focusing on proprietary solid forms tailored to patient needs [5] Future Outlook - The company is committed to advancing its pipeline and expects to reach key results and milestones in the near term, positioning itself for growth and development in the autoimmune disorder treatment space [6]
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904